Tonix Pharmaceuticals Holding Corp.
NASDAQ Capital MarketTotal Valuation
Tonix Pharmaceuticals Holding Corp. carries a market capitalization of 154.63M, placing it among publicly traded companies globally. Its enterprise value stands at 39.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 154.63M |
| Enterprise Value | 39.31M |
Share Statistics
Tonix Pharmaceuticals Holding Corp. currently has 16.79M shares outstanding.
| Shares Outstanding | 16.79M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 5.60, and the price-to-book ratio stands at 0.96.
| PE Ratio | N/A |
| PS Ratio | 5.60 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | -1.10 |
| P/OCF Ratio | -1.06 |
Enterprise Valuation
| EV / Sales | 1.35 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Tonix Pharmaceuticals Holding Corp. maintains a current ratio of 6.61, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.61 |
| Quick Ratio | 6.22 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -81.82 |
| Return on Assets (ROA) | -72.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.81 |
Stock Price Statistics
Tonix Pharmaceuticals Holding Corp.'s stock has declined approximately -60.72874% over the past 52 weeks. The 50-day moving average sits at 11.91, while the 200-day moving average is 13.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | -60.72874% |
| 50-Day Moving Average | 11.91 |
| 200-Day Moving Average | 13.84 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Tonix Pharmaceuticals Holding Corp. generated 29.10M in revenue and converted that into -159.67M in net income, yielding earnings per share of -12.51. EBITDA reached -161.65M, while operating income came in at -163.77M.
| Revenue | 29.10M |
| Gross Profit | 24.40M |
| Operating Income | -163.77M |
| Pretax Income | -159.67M |
| Net Income | -159.67M |
| EBITDA | -161.65M |
| EBIT | -163.77M |
| Earnings Per Share (EPS) | -12.51 |
Balance Sheet
Tonix Pharmaceuticals Holding Corp. holds 176.23M in cash and equivalents against 1.27M in total debt, resulting in a net debt position of -176.23M. Total book value stands at 222.28M, with working capital of 172.65M providing operational flexibility.
| Cash & Cash Equivalents | 176.23M |
| Total Debt | 1.27M |
| Net Debt | -176.23M |
| Equity (Book Value) | 222.28M |
| Book Value Per Share | 13.24 |
| Working Capital | 172.65M |
Cash Flow
Tonix Pharmaceuticals Holding Corp. produced -152.99M in operating cash flow over the past twelve months. After subtracting -5.11M in capital expenditures, free cash flow totaled -158.11M - equivalent to -12.39 per share.
| Operating Cash Flow | -152.99M |
| Capital Expenditures | -5.11M |
| Free Cash Flow | -158.11M |
| FCF Per Share | -12.39 |
Margins
Tonix Pharmaceuticals Holding Corp. operates with a gross margin of 83.83, reflecting its pricing power and cost economics. The operating margin of -562.75 and net profit margin of -548.64 provide insight into operational efficiency.
| Gross Margin | 83.83 |
| Operating Margin | -562.75 |
| Pretax Margin | -548.64 |
| Profit Margin | -548.64 |
| EBITDA Margin | -555.46 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -96.94 |
| FCF Yield | -90.78 |
Stock Splits
Tonix Pharmaceuticals Holding Corp.'s most recent stock split took place on February 5, 2025 with a 100:1 split ratio.
| Last Split Date | 2/5/2025 |
| Split Ratio | 100:1 |
Scores
Tonix Pharmaceuticals Holding Corp. posts an Altman Z-Score of -2.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.31 |